GlassScriptPhysician profile
Huey Metts
NPI 1841606274
$7,489.55
in general payments reported to CMS, 2019-2025
28 companies · $557 in 2025
The $557 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,079 · 2022: $1,367 · 2023: $2,466 · 2024: $2,020 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,044.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $995.56 | 2021-2025 | Farxiga, Airsupra |
| Abbvie INC. | $902.03 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $785.67 | 2023-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $714.37 | 2022-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $568.47 | 2023-2024 | Lifevest |
| Amgen INC. | $476.40 | 2021-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $434.70 | 2023-2024 | Xarelto |
| Esperion Therapeutics, INC. | $342.42 | 2021 | |
| Merck Sharp & Dohme LLC | $341.24 | 2023-2024 | Verquvo |
| Abbott Laboratories | $317.80 | 2023-2024 | Assurity, Aveir, Jot Dx |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $261.86 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $225.79 | 2022 | |
| Boston Scientific Corporation | $192.86 | 2023-2025 | Watchman Access System, General - Therapies, Watchman Flx |
| Medtronic, INC. | $144.07 | 2023 | Micra |
| Pfizer INC. | $124.60 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $121.63 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $98.45 | 2022 | |
| Alkermes, INC. | $96.24 | 2022 | |
| Lilly USA, LLC | $94.86 | 2021-2025 | Mounjaro |
| Novo Nordisk INC | $52.52 | 2023-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $32.96 | 2021 | |
| Glaxosmithkline, LLC. | $31.30 | 2021-2025 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $28.87 | 2023-2024 | |
| Exact Sciences Corporation | $28.85 | 2025 | Cologuard Collection Kit |
| Atricure, INC. | $23.64 | 2023 | |
| Dexcom, INC. | $19.84 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.04 | 2024 | Onpattro |
| Kiniksa Pharmaceuticals, LTD. | $14.51 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huey Metts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.